This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).
Uneven access to multiple myeloma (MM) treatment, particularly daratumumab, which was approved to treat the uncommon blood cancer in 2015, may be influenced by racial disparities between Black patients and White patients, according to research published recently in Clinical Lymphoma, Myeloma & Leukemia.
Data from clinical trials at Levine Cancer Institute in Charlotte, North Carolina, and Weill Cornell Medicine in New York, New York, that encompassed patient characteristics, treatment patterns, and patient outcomes—overall response rate (ORR), progression-free survival, and time to next line of therapy (LOT)—bear out these retrospective chart review findings for the adult patients (n = 89 Black patients; n = 163 White patients) who began any-line daratumumab treatment between November 16, 2015, and May 2020.
“While its safety and efficacy are well documented, there is limited real-world information on its use and outcomes in patients of different races,” the authors wrote. “Real-world data on the use of therapeutics and clinical outcomes in patients with MM of different races can help to determine whether disparities exist in the US, which could guide the improvement of diagnostic, preventative, and therapeutic approaches.”
The Black patients in the study were younger at their diagnosis, had approximately a 27% longer waiting period between their MM diagnosis and starting daratumumab, and had more therapies prior to daratumumab initiation compared with the White patients:
More Black patients received 3 or more prior LOTs before starting on daratumumab vs White patients, at 55.1% compared with 36.8%, with similar trends seen among those who received proteasome inhibitors or immunomodulatory drugs, at 96.5% vs 93.9% and 95.3% vs 89.9%, respectively.
However, even though MM stage and cytogenetic profiles were similar overall, more Black patients than White patients had unknown cytogenetic risks (59.6% vs 45.4%) and more White patients than Black patients had a high-risk cytogenetic profile (37.1% vs 22.2%). In addition, for a subanalysis that looked at initiating daratumumab in the second line, fewer Black patients had high-risk cytogenetic profiles vs White patients (9.4% vs 20.3%) but a longer time from diagnosis to treatment initiation (45.1 vs 37.4 months).
Trends for treatment initiation in the first, second, and third lines differed between the patient groups:
Significant variations were not seen between the patient groups in any of the 3 principal outcomes.
More White than Black patients were on a quadruplet regimen containing daratumumab (7.4% vs 1.1%) for their first treatment with the medication, but that this treatment duration was longer among White patients, at 10.6 vs 9.0 months.
The ORR was identical for both patient groups when starting daratumumab as a first-line treatment, at 100%; in the second line, this was 90.9% for Black patients and 82.9% for White patients; and in the third line, 67.6% and 65.4%, respectively. Very good partial response rates were also higher for the Black patients in the 3 treatment initiations. Overall, however, ORRs were similar for the study, at 70.6% and 70.3% for Black patients and White patients, respectively (adjusted odds ratio, 1.06; P = .843).
In addition, although median times to disease progression (13.5 vs 17.9 months) and to next treatment (13.4 vs 15.6 months) were shorter among the Black patient population compared with the White patient population, adjusting for age and prior lines of therapy negated these findings.
“Although responses to newer medications are similar across racial/ethnic groups, African Americans may not be reaping the full benefit of these treatments,” the authors wrote. “Moreover, while there were no differences between groups in treatment duration and response to daratumumab, Black patients received more lines of therapy overall prior to the initiation of daratumumab. Thus, Black patients may have had later access to daratumumab than White patients.”
They highlight that their findings suggest daratumumab access is persistently uneven and that health care disparities in the United States require ongoing efforts to overcome.
“Ongoing research highlighting such disparities and their causes across disease areas,” they concluded, “is essential for informing strategies to reduce inequality in health care.”
Reference
Atrash S, Thompson-Leduc P, Tai M-H, et al. Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: a real-world chart review study. Clin Lymphoma Myeloma Leuk. 2022;22(8):e708-e715. doi:10.1016/j.clml.2022.03.014
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More